Picture of Coretag logo

JMKJD Coretag Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeMicro Cap

Momentum

Relative Strength (%)
1m+128440.93%
3m+121207.23%
6m+104198.36%
1yr+107864.6%
Volume Change (%)
10d/3mn/a
Price vs... (%)
52w Highn/a
50d MAn/a
200d MAn/a

Growth & Value

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capitaln/a
Return on Equityn/a
Operating Marginn/a

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
30th Sep 202430th Sep 2025
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2024 / 2025

Blurred out image of Coretag EPS forecast chart

Profile Summary

Coretag, Inc. is focused on the development of cancer imaging and targeted radiotherapy, based on its Necrosis Targeting Platform Technology (NTPT). The Company developed NTPT as a result of the discovery of a group of cyanine dyes which have selective targeting properties for intracellular proteins. These proteins become available for binding only when the cell membrane loses its integrity, which occurs once a cell has become necrotic. The Company has developed a portfolio of products that address high unmet needs in oncology. The Company develops targeted radiotherapy with 177Lu (lutetium) and 121Pb (lead) for the treatment of rapidly growing tumors and metastasis. It also develops targeted diagnostics with 89Zr (zirconium) and 111In (indium) for detecting and quantifying necrotic tissue in the human body.

Directors

Last Annual
September 30th, 2023
Last Interim
December 31st, 2023
Incorporated
September 12th, 2014
Public Since
November 17th, 2015
No. of Shareholders
40
Sector
Healthcare Equipment & Supplies
Industry
Healthcare
Exchange
us flag iconPink Sheets on Nasdaq
Shares in Issue
90,000
Blurred out image of a map
Address
7325 Oswego Road, LIVERPOOL, 13090
Web
Phone
+1 3154517515
Auditors
Gries & Associates, LLC

JMKJD Share Price Performance

Upcoming Events for JMKJD

Similar to JMKJD

Picture of Aamaxan Transport logo

Aamaxan Transport

us flag iconPink Sheets on Nasdaq

Picture of ACCUSTEM SCIENCES logo

ACCUSTEM SCIENCES

us flag iconPink Sheets on Nasdaq

Picture of ADM Tronics Unlimited logo

ADM Tronics Unlimited

us flag iconPink Sheets on Nasdaq

Picture of Aksys logo

Aksys

us flag iconPink Sheets on Nasdaq

FAQ